NVN Liquidation, Inc.
DelistedCIK 1467154fmd_1NS2D6DEZGM9KTB8FRARY1DZGBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Mar 31, 2023, 34 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | 3 | 6 | 5 | 5 | 3 | 24 |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 7 |
| Gross profit | – | – | – | – | – | – | – | 3 | 16 |
| Research and development | 7 | 17 | 46 | 25 | 23 | 25 | 20 | 20 | 16 |
| Selling, general and administrative | – | – | – | – | – | – | – | 12 | 34 |
| Total operating expenses | 12 | 26 | 60 | 38 | 35 | 36 | 35 | 33 | – |
| Operating income | (12) | (26) | (60) | (36) | (29) | (31) | (30) | (30) | (34) |
| Interest expense | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Interest and investment income | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 0 | 0 | (1) | (1) | 0 | 1 | 0 | 3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (13) | (26) | (60) | (37) | – | – | – | – | – |
| Net income | (11) | (28) | (60) | (37) | (29) | (30) | (29) | (30) | (31) |